ArticleActa pharmacologica Sinica2026

Targeting RSK2 enhances the efficacy of IGF1R inhibitor against triple-negative breast cancer via antagonizing IGF1/IGF1R signaling mediated by GATA3-IGFBP5 pathway.

Tian-Jiao Shan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.